

# Curriculum vitae

Name: Professor Thomas Gruenberger, MD

Address: Clinicum Favoriten  
HPB Center, Vienna Health Network  
Department of Surgery  
Kundrat Street 3  
1100 Vienna, Austria  
Tel: +43 1 60191 4108  
Fax: +43 1 60191 4109

## SCHOOL CAREER:

1970-1974: Primary school in Vienna (VS Albertus Magnus)  
1974-1982: High school (Akademisches Gymnasium) in Vienna, final exams passed on 31 May 1982

## UNIVERSITY CAREER:

1982-1991: Medical studies at University of Vienna, Vienna Austria  
**Diploma granted (M.D.):** 13 March 1991  
04. 09. 1991: Military service in the military hospital of Vienna (Heeresspital Wien)

## POSTGRADUATE QUALIFICATION:

31. 01. 1998: **State registration as fully trained specialist in General Surgery**  
01. 04. 2001: **Specialist in Hepato-biliary Surgery**  
11. 06. 2002: **Associate Professor of Surgery, University of Vienna**  
01. 04. 2009: **State registration as Specialist in Visceral Surgery**

## POSTGRADUATE APPOINTMENTS:

04.91-01.98 **Registrar in Surgery**, University of Vienna  
04.97-09.97 **Senior Registrar/Consultant**, University of Vienna & Surgical Department KH Baden (district hospital, Austria)

04.99 – 01.2000	<b>Liver unit</b> Prof. DL. Morris, St. George Hospital, UNSW, Sydney; <b>Research Fellow</b>
02.00 – 03.01	<b>Department of Surgery, St. George Hospital</b> , University of New South Wales, Sydney, Australia; <b>Senior Lecturer in Surgery</b> ; <b>Deputy Chief liver unit</b> (Chief: Prof DL Morris)
05.01- 03.14	<b>Consultant</b> , Department of General Surgery; <b>Head</b> Hepatobiliary Service, Department of General Surgery, University of Vienna
04.14-03.18	<b>Professor and Chair</b> , Department of Surgery I Rudolfstiftung Hospital, KAV, Vienna
04.16-current	<b>Full Professor of Surgery</b> , Medical University Vienna
11.16-current	<b>Professor and Chair</b> HPB Surgery, Sigmund Freud Private University, Vienna
04.18-current	<b>Professor and Chair</b> , Department of Surgery Clinicum Favoriten, HPB Center, Vienna Health Network, Vienna
05.19-current	<b>Director Surgical Oncology</b> , Vienna Cancer Center, Vienna

#### PAST AND PRESENT LEADING POSITIONS:

2003.	Head HPB-branch Austrian Society of Surgical Oncology
2005.	Secretary-General Austrian Society of Surgical Oncology
04.2006	Member of the Pan-European Consensus Conference for the Treatment of Colorectal Cancer Liver Metastases
06.2007	Member of the colorectal task Force of the ABCSG
09.2008	<b>Executive Board member, European Society of Surgical Oncology (ESSO)</b>
10.2008	President elect, Austrian Society of Surgical Oncology
01.2009	Associate Editor of the HPB Section of the European Journal of Surgical Oncology
05.2009	<b>Vice-Editor in Chief</b> , European Journal for Digestive Oncology
10.2009	<b>Board member of the UEMS Division of HPB Surgery</b>
03.2010	Head of the Liver Task Force of the Austrian Breast and Colorectal cancer Study Group (ABCSG)
09.2010	<b>ETC</b> (education&training commity) <b>Board Member, ESSO</b>
10.2010	<b>Advisory Council Member</b> of the European Society of Digestive Oncology ( <b>ESDO</b> )
10.2010	<b>President</b> , Austrian Society of Surgical Oncology
09.2012	<b>Chair Membership committee, ESSO</b>

01.2013	<b>Governing Board Member, ESDO</b>
04.2014	<b>Professor and Chairman</b> , Department of Surgery I; Rudolfstiftung Hospital, Vienna, Austria
04.2016	<b>Full Professor of Surgery</b> , Medical University Vienna
11.2016	<b>Professor and Chair HPB Surgery</b> , Sigmund Freud Private University, Vienna
04.2018	<b>Professor and Chairman</b> , Department of Surgery, Clinic Favoriten, HPB Center, Health Network Vienna
05.2019	<b>Director</b> Surgical Oncology, Vienna Cancer Center
01.2021	<b>ESMO Faculty</b> , member of the Gastrointestinal-tumor group
01.2023:	<b>President</b> Austrian Association of Hepato-Pancreato-Biliary Surgery (AAHPBS), chapter of the E-AHPBA
03.2023	<b>Member Research Council</b> , Sigmund Freud University, Vienna

#### **Editorial Board of peer reviewed Journals**

European Surgery (Acta Chirurgica Austriaca) 05.2004  
 Journal Gastroenterology and Hepatology 02.2004  
 European Journal of Surgical Oncology 01.2009-12.2011  
 Journal of Digestive Oncology 01.2009  
 Annals of Surgical Oncology 06.2010  
 European Journal of Surgical Oncology; editorial advisory board HPB 09.2013  
 Journal Hepatobiliary & Pancreatic Diseases International 06.2015  
 der Chirurg 12.2015

#### **Reviewer for peer reviewed scientific journals**

European Surgery 05.2004  
 Journal Gastroenterology and Hepatology 02.2004  
 European Journal of Surgical Oncology 12.2006  
 British Journal of Surgery 09.2007  
 Journal of Clinical Oncology 04.2008  
 Clinical Colorectal Cancer 05.2008  
 Reviews on Recent Clinical Trials 07.2008  
 BMC Cancer 11.2008  
 Magazine of European Medical Oncology 01.2009  
 Annals of Surgical Oncology 04.2009  
 Annals of Surgery 10.2009  
 Lancet Oncology 06.2010  
 Annals of Oncology 03.2011

European Journal of Cancer 07.2011  
Archives of Surgery 04.2012  
Plos One 08.2013  
Critical Reviews in Oncology/Hematology 03.2014  
Journal of Hepatology 08.2014  
der Chirurg 12.2015  
Colorectal Disease 08.2016  
Langenbeck's Archive of Surgery, 12.2016  
Therapeutic advances in medical oncology, 05.2018  
EBioMedicine, 03.2019  
ESMOOpen, 04.2021  
Hepatobiliary Surgery and Nutrition, 11.2021

**MEMBERSHIP OF LEARNED SOCIETIES:**

Austrian Society for Surgery (ÖGC, since 1992)  
German Society for Surgery (DGC, since 1997)  
European Society of Transplantation (ESOT, since 1995)  
Austrian Society of Transplantation (ASOT, since 1992)  
Working Party for Minimally Invasive Surgery (AMIC) of the ÖGC (since 1994)  
Austrian Society for Gastroenterology and Hepatology (since 1995)  
European Digestive Surgery (CICD and EDS, since 1998)  
Transplantation Society of Australia and New Zealand (since 2000)  
International Hepato Pancreato Biliary Association (since 2000)  
The Transplantation Society (since 2000)  
European Organisation of Research and Treatment of Cancer, EORTC (since 2002)  
European Society of Surgical Oncology (since 2003)  
European Society of Medical Oncology (since 2003)  
Austrian Society of Haematology and Oncology (since 2004)  
American Society of Clinical Oncology (since 2004)  
Faculty of the Gastro Intestinal Cancer Society (since 2005)  
Deutsche Krebsgesellschaft (DGK since 2021)  
Deutsch Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV since 2024)

**ADVISORY ROLE:**

- Sanofi-Aventis, since 05.2005
- Bayer, since 11.2008
- Roche, since 01.2009
- Pfizer, since 06.2009

- Merck Serono, since 01.2011
- Amgen, since 05.2013
- Eli Lilly, since 09.2015
- Servier, since 06.2016
- Humedics, since 04.2018
- Johnson&Johnson, since 06.2018
- BMS, since 09.2018
- MSD, since 02.2019
- Olympus, since 10.2020
- Incyte, since 01.2021
- AstraZeneca, since 04.2022
- Baxter, since 05.2022
- Johnson&Johnson, since 10.2024
- Astellas, since 12.2024

#### **POSTGRADUATE COURSES:**

- European College of Transplantation (Hesperis; Rom1992; Munich 1993)
- Austrian Clinical Oncology symposium: breast cancer (Salzburg, Austria 1993)
- Austrian Clinical Oncology symposium: colon cancer (Poertschach, Austria 1995)
- Workshop liver tumors (Mainz, Germany 1996)
- Update Internal medicine (Vienna, Austria 1997)
- Austrian Clinical Oncology symposium: rectal cancer (Villach, Austria 1997)
- International Workshop on hepatic Cryosurgery (Neijmegen, NL 1998)
- Advanced course for vascular surgeons (Zermatt, CH 1998)
- Central European Transplant Workshop (Prag, CZ 1998)
- Austrian Clinical Oncology symposium: liver cancer (Poertschach, Austria 1998)
- Laparoscopic Nephrectomy Workshop (Sydney, Australia 2000)
- Current concepts in Liver Surgery at Hospital Henri Mondor, Prof Daniel Cherqui and Hospital Paul Brousse, Prof Henri Bismuth (Paris, France 2001)
- Workshop Radiofrequency Ablation techniques (Milan, Italy 2002)
- CoMITT (Congress of minimal invasive tumor therapy) including Workshop percutaneous RFA (Munich, Germany 2003)
- Workshop Abdominal MRT Imaging (Pöchlarn, Austria 2003)
- Workshop interventional treatment strategies of HCC (Vienna, Austria 2003)
- Masterclass in laparoscopic colorectal surgery (Paris, France 2003)

- New Technologies in Liver Surgery (Strassbourg, France 2004)
- Gastrointestinal neuroendocrine tumors, actual treatment strategies (Vienna, Austria 2005)
- Angiogenesis: a key target in Oncology (Barcelona, Spain 2008)
- Drug safety and efficacy testing course; clin. Pharmacology (Vienna, Austria 2008)
- Advanced Course in CRC liver metastases management (Bordeaux, France 2010)
- Multidisciplinary Treatment of Colorectal Cancer Liver Metastases (San Francisco, USA 2012)
- Masterclass on laparoscopic surgery of the liver and pancreas (Paris, France 2014)
- Masterclass of minimal invasive colorectal surgery (Vienna, Austria 2014)
- Masterclass Pancreatic Surgery (Heidelberg, Germany 2018)
- Masterclass Laparoscopic HPB Surgery (Leuven, Belgium 2018)
- Masterclass Laparoscopic Hepatic Surgery (Milano, Italy 2018)
- Clinical Immersion laparoscopic colon surgery (Linz, Austria 2019)
- ESGAR HPB & GI neoplasms (Valencia, Spain 2019)
- 17th Shanghai International CRC Symposium (Shanghai, China 2021)
- 3<sup>rd</sup> Austrian Roboter Congress (Vienna, Austria 2022)

**PHD THESIS ADVISOR AND SUPERVISOR:**

- Doz. Dr. Harald Puhalla
- Doz. Dr. Birgit Gruenberger
- Doz. Dr. Dietmar Tamandl
- Doz. Dr. Markus Klinger
- PD. Dr. S. Stremitzer
- PD P. Starlinger, MD PhD

**Surgical Oncology and hepato-biliary Surgery CONSULTANT:**

- Goetlicher Heiland Hospital; Vienna
- Mistelbach Hospital; Lower Austria
- Amstetten Hospital; Lower Austria
- Floridsdorf Hospital, Vienna
- Rudolfstiftung Hospital, Vienna
- Baden Hospital; Lower Austria

- Doebling Privat Clinic, Vienna
- Private University Hospital, Salzburg
- Oberpullendorf Hospital; Burgenland, Austria

### **RESEARCH GRANTS:**

- Novartis Research Grant – 1996: study to evaluate supplemental enteral nutrition in clinical liver resection; 100.000,- ÖS
- Viennese Mayor Council Grant – 1998: study to evaluate glycine supplementation in preventing nephrotoxicity after liver transplantation; 175.000,- ÖS
- Viennese National Bank Grant – 1998: study evaluating early postoperative feeding and outcome in ICU patients after major intracranial bleeding; 130.000,- ÖS
- Novartis Research Grant – 1999: study to investigate immunological changes and outcome in colorectal cancer patients perioperatively fed with an immunenhancing diet; 330.000 ÖS
- Viennese Major Council Research Grant – 2003: liver metastases after colorectal cancer; influence of specific genetic alterations on prognosis and response to chemotherapy; 17.000,- €
- Viennese Major Council Research Grant – 2008: influence of Bevacizumab upon systemic angiogenesis capacity; 30.000,- €
- Austrian National Bank Research Grant – 2012: response prediction to chemotherapy in mCRC; 108.000,-€

### **COMPETITIVE RESEARCH GRANTS THROUGH PARTICIPATION IN INTERNATIONAL STUDIES:**

- Metastatic Colorectal Cancer: app. 240.000,- €
- Hepatocellular Cancer: app 200.000,- €

### **STUDY PARTICIPATION (PHASE II-III):**

- EORTC 40983: periOP CTx vs Surgery alone in resectable colorectal cancer liver metastases; Phase III; 2002-05 (ref: Lancet 2008, Annals Surgery 2012, Lancet Oncology 2013)
- CELIM 1: Folfox/Folfiri plus Cetuximab in initially unresectable colorectal cancer liver metastases; Phase II; 2004-08 (ref: Lancet Oncology 2010, Annals Oncology 2014)

- ASSO-LM1: Pre- and postOP chemotherapy including Bevacizumab in potentially curable mCRC; phase I/II; 2006-08 (ref: JCO 2008)
- OLIVIA: Folfox6/FOLFOXIRI plus Bevacizumab in unresectable colorectal cancer liver metastases; Phase II; 2008-11 (ref: Ann Oncology 2014)
- STORM: Sorafenib vs Placebo in potentially curative treated HCC; Phase III; 2007-10 (ref: ASCO Proceedings 2014)
- BMS CA209-9DX: Nivolumab vs Placebo after curative resection or ablation of high risk HCC; Phase III; 2018 - 20 (currently FU)
- DRAGON 1/2: Portal vein and hepatic vein occlusion to induce rapid hypertrophy of the future liver remnant; Phase II-III; 2021-ongoing
- ACTICCA: Adjuvant therapy with GemCis vs Capecitabine after curative intent resection of CCC; phase III; 2014-ongoing
- IMBRAVE 251: Open-label, randomized study of Atezolizumab with Levantinib or Sorafenib vs Levantinib or Sorafenib alone in HCC previously treated with Atezolizumab and Bevacizumab; phase III; 2020-ongoing
- GAIN: neoadj chemotherapy with GemCis followed by liver resection vs immediate LR alone with or without adjuvant CTx in BTC; phase III; 2021-ongoing
- MORPHEUS: a phase Ib/II, open-label, multicenter, randomized platform study evaluating the efficacy and safety of neoadjuvant immunotherapy in patients with surgically resectable hepatocellular carcinoma (Morpheus-NEO HCC); 2024-ongoing

### **CONGRESS ORGANISATION AND MANAGEMENT:**

- Annual Meeting of the Austrian Society of Surgical Oncology; President, September 2004, Salzburg Austria
- Annual Live OP-Workshop, Multidisciplinary Treatment of Liver Tumours; President, April 2006, General Hospital Vienna, Austria
- 1<sup>st</sup> Surgical Advisory Board Meeting on the treatment of colorectal liver metastases; President, March 2008, Vienna Austria
- Work-Shop “DeLiver Excellence”, current treatment algorithm in mCRC; September 2009; Vienna, Austria
- Work-Shop “DeLiver Excellence”, current treatment algorithm in mCRC; November 2009; Loipersdorf, Austria
- Work-Shop “DeLiver Excellence”, current treatment algorithm in mCRC; October 2010; Krems, Austria
- CRC-Forum Meeting for French mCRC MDT meeting representatives; November 2011; MUW-CCC, Vienna, Austria

- CRC-Forum Meeting for Finnish mCRC MDT meeting representatives; March 2012; MUW-CCC, Vienna, Austria
- Perceptorship CRC-Management, course director; May 2012
- CLM Management, scientific director; May 2012; CCC Milano, Italy
- CLM Management, scientific director; May 2012; CCC Genova, Italy
- 30<sup>th</sup> Annual Meeting of the Austrian Society of Surgical Oncology; President, October 2013, St. Wolfgang, Austria
- Advanced Course on Primary Liver Tumours, scientific coDirector; April 2014; Liverpool, UK
- 14<sup>th</sup> postgraduate course of the Belgian Society of Surgery: colrectal liver metastases, anno 2014, President; October 2014; Mechelen, Belgium
- ESSO liver tumors: from basics to advanced care; scientific and logistic director, September 2015; Vienna, Austria
- ESSO course: advanced course on the management of colorectal liver metastases; scientific co-chair, October 2016, Bordeaux, France
- ESSO course: from basic to advanced care in surgical oncology; scientific chair, September 2017, Vienna, Austria
- ESSO course: advanced course on the management of colorectal liver metastases; scientific co-chair, November 2018, Bordeaux, France
- Laparoscopic HPB Masterclass, May 2019, Vienna, Austria
- ESMO-GI Conference July 2020virtual, Barcelona, Spain
- Laparoscopic HPB Masterclass II, May 2021, Vienna, Austria
- ESMO-GI Conference, July 2021 virtual, Barcelona, Spain
- 20<sup>th</sup> Austrian SurgeryDay, November 2021, Baden, Austria
- HPB Masterclass III, May 2022, Vienna, Austria
- ESMO-GI Conference, July 2022, Barcelona, Spain
- ESDO-BGDO Masterclass multidisciplinary challenges in GI cancer, Brussels November 2022
- 21<sup>th</sup> Austrian SurgeryDay, November 2022, Baden, Austria
- HPB Masterclass IV, January 2023, Vienna, Austria
- 25<sup>th</sup> ESMO-GI Conference, June 2023, Barcelona, Spain
- HPB Masterclass V, September 2023, Vienna, Austria
- 22<sup>nd</sup> Austrian SurgeryDay, November 2023, Baden, Austria
- 26<sup>th</sup> ESMO-GI Conference, June 2024, Munich, Germany
- HPB Masterclass VI, June 2024, Vienna, Austria
- HPB Masterclass VII, May 2025, Vienna, Austria
- 27<sup>th</sup> ESMO-GI Conference, July 2025, Barcelona, Spain

### **MEMBER OF CONSENSUS CONFERENCES:**

- European Consensus of treating colorectal cancer liver metastases (2006 onwards, several international locations)
- Merck International Consensus on treating mCRC (Vienna 2007)
- Merck Austrian Consensus on treating mCRC (Vienna 2007)
- Merck European Advisory network of treating mCRC (Athens 2007)
- Bayer Austrian Consensus on future prospective of Sorafenib in the treatment of HCC (Vienna 2008)
- Merck Surgical Consensus on treating colorectal cancer liver metastases (Vienna 2008)
- European Consensus Group Glcancer (Barcelona 2008, 2009)
- Merck European Advisory Consensus Treatment mCRC (Zuerich 2011)
- EGFR Advisors Network mCRC (Vienna 2011)
- ESMO-ESSO-ESTRO consensus guidelines treating cholangiocarcinoma (Web based 2014)
- ESMO consensus conference on metastatic colorectal cancer (Zuerich 2014)
- E-AHPBA Consensus Meeting, preOP liver assessment before liver resection (Innsbruck 2022)
- E-AHPBA Consensus Meeting, treatment synchronous CRLM (Saragossa 2022)
- Austrian Consensus Meeting: Guidelines systemic treatment of cholangiocellular carcinoma (Vienna 2022)
- European Consensus Meeting on peri- and postoperative Management following Liver Resection (Innsbruck 2024)
- Consensus Conference colorectal liver metastasis (Houston, Texas 2026)

### **Visiting Professorship:**

- Turin, Ospedale Mauriziano Umberto I, June 2013
- Montreal, McGill University, May 2014

### **Health Care Positions:**

- Member of the Specialization Action Committee of the Austrian Society of Surgery
- Board Member of the Gesundheit Österreich (ÖBIQ)
- Board Member of the national Austrian Society of Surgery Council (2010-13)
- Trial coordinator Surgical Oncology, ESSO
- ESMO Faculty member GI-tumors, ColoRectal Group (2021-25)
- Prevenire - Forum Alpbach, Oncology 2030 (2021-22)

**Health Care Management:**

- retrieval and selection of Coworkers (MUW, Vienna February 2011)
- ICH GCP training (last updated Syneos Health, September 2022)

**Health Care Scientific Reviews:**

- Review of Applicants for the National Bank Grant (2010, 2011)
- Review of Applicants for the UK Cancer Research (2012)
- Review of Applicants for National Bank Fond (2016, 2018)
- Review Professorship Medical University Vienna (2022)

**SCIENTIFIC REFERENCES:**

The reference list comprises over **200 citations** in national and international journals and over **500 citations** of lecturing and presentations at international conferences.

The articles are divided into:

•) **218 Original articles:**      **90 as leading or senior author**

**128 as Co-author**

•) **> 500 referenced lectures and cited abstract**

•) **15 book contributions, 2 books Editing**

•) **> 300 Congress reports**

•) **> 350 invited Lectures**

**Impact Factor total:**                    **1120,055**

**Impact Factor first or senior author:** **404,601**



Vienna, December 2025

Th Gruenberger, MD